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The meta-analysis of early goal-directed therapy (EGDT) by Gu and colleagues in the previous issue of Critical Care
adds to the ongoing controversy about the value of EGDT for resuscitating patients with severe sepsis and septic
shock. The results of the ProCESS (protocolized care for early septic shock) and ARISE (Australasian resuscitation in
sepsis evaluation) trials failed to demonstrate any benefit of EGDT or protocolized resuscitation when compared
with ‘usual care’. The questions are the following: What is ‘usual’ care? What is ‘real world’ care? Do the results of a
robust and well-conducted randomized controlled trial - in which many patients may be excluded for a variety of
reasons - reflect the care given to patients on a daily basis in our emergency departments and intensive care units?
Of course, there are no obvious answers to these questions, and many clinicians look forward to managing these
patients without protocols. For now, the data do seem to support the management of patients with septic shock
without mandated central lines or protocols. Does this mean we should go back to the era of ‘do whatever you
want’? No consensus exists among clinicians regarding optimal hemodynamic monitoring, and to date no method
has been proven to be superior. Given the amount of fluids given prior to randomization in the ProCESS and ARISE
trials, ‘usual care’ appears to now include aggressive, early fluid resuscitation with at least 20 mL/kg of crystalloid
and rapid administration of appropriate antibiotics. Certainly, this reflects the impact of the original trial by Rivers
and colleagues and the broad-based implementation of the Surviving Sepsis Campaign Guidelines and bundles. If
this continues to define ‘usual care’, then perhaps it is no longer necessary to mandate specific protocols for resuscitation,
as it appears that standard sepsis management has evolved to be consistent with published protocols.Introduction
The meta-analysis of early goal-directed therapy (EGDT)
by Gu and colleagues [1] in the previous issue of Critical
Care adds to the ongoing controversy about the value of
EGDT for resuscitating patients with severe sepsis and
septic shock. The results of the ProCESS (protocolized
care for early septic shock) [2] and ARISE (Australasian
resuscitation in sepsis evaluation) [3] trials have been
interpreted by some to sound the death knell for EGDT
and the value of protocol-driven resuscitation in these
critically ill patients. Both of these trials failed to demon-
strate any benefit of EGDT or protocolized resuscitation
when compared with ‘usual care’. However, aspects of
the two trials provoke concerns about comparing them
with the original study by Rivers and colleagues [4],
including population severity, administration of fluids
prior to randomization, and the overall mortality rate.Correspondence: mitchell_levy@brown.edu
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In the meta-analysis by Gu and colleagues (which in-
cluded the ProCESS but not the ARISE trial), a significant
survival benefit from EGDT was found in seven trials - all
randomized controlled trials (RCTs) - in the subgroup of
‘early’ intervention trials (that is, within 6 hours). How-
ever, by the authors’ own admission, the meta-analysis
was flawed because of a high risk of bias due to the uncer-
tain methodology of some of the trials. Though weakened
by the fact that four of the included studies were published
only in Chinese-language journals, this meta-analysis and
another recently published study [5] raise questions about
how to generalize the results of the ProCESS and ARISE
trials.
The challenge for practicing clinicians is how to
understand ‘usual care’ in the settings of these large
RCTs. In both the ProCESS and ARISE trials, the usual
care mortality was 18%. That is a remarkably low mor-
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practice, given the low acuity - Acute Physiology and
Chronic Health Evaluation II scores - and short intensive
care unit length of stay in these two trials, and whether
these results can be generalized to a sicker population
seen outside the confines of an RCT in which ‘real world’
patients are excluded.
The questions are the following: What is ‘usual’ care?
What is ‘real world’ care? Do the results of a robust and
well-conducted RCT - in which many patients may be
excluded for a variety of reasons - reflect the care given
to patients on a daily basis in our emergency depart-
ments and intensive care units? Does a mortality rate of
18% represent a realistic goal in 2014? Are clinicians and
hospitals prepared to be held to that mortality rate by
the public and third-party payers? In the US, man-
dated public reporting of sepsis is now a reality in
one state [6], and preparations are under way nation-
ally to use sepsis measures for public reporting in just
a few years. Will regulatory agencies hold clinicians to this
mortality rate?
Of course, there are no obvious answers to these ques-
tions, and many clinicians look forward to managing
these patients without protocols. For now, the data do
seem to support the management of patients with septic
shock without mandated central lines or protocols. How-
ever, almost two thirds of the patients in the two large
RCTs were on pressors; therefore, the large majority of
patients in both the ProCESS and ARISE trials were man-
aged with the use of central lines.
Fortunately for patients and clinicians, the opportunity
to address the question of what comprises ‘usual care’
will emerge over the next several years as state and
national reporting takes hold [6,7]. Metrics will be collec-
ted from large populations of patients with severe sepsis
and septic shock on the various modalities of monitoring
available for clinicians to choose from, including physical
examination. Over time, analyses of these large databases
should create clarity about the use of hemodynamic moni-
toring and protocolized care as ‘routine care’ in guiding
clinicians to improve outcomes of patients with this com-
mon illness. Meanwhile, clinicians and hospitals should
continue to dedicate time and resources to establish sys-
tems to identify these patients early and begin treatment
rapidly after identification. Most still agree that when it
comes to sepsis, the earlier we treat, the better.
Conclusions
Does this mean we should go back to the era of ‘do
whatever you want’? No consensus exists among clini-
cians regarding optimal hemodynamic monitoring, and
to date no method has been proven to be superior.
Given the amount of fluids given prior to randomization
in the ProCESS and ARISE trials, ‘usual care’ appears tonow include aggressive, early fluid resuscitation with at
least 20 mL/kg of crystalloid and rapid administration of
appropriate antibiotics. Certainly, this reflects the impact
of the original trial by Rivers and colleagues [4] and the
broad-based implementation of the Surviving Sepsis
Campaign Guidelines and bundles [8]. If this continues
to define ‘usual care’, then perhaps it is no longer neces-
sary to mandate specific protocols for resuscitation, as it
appears that standard sepsis management has evolved to
be consistent with published protocols. That would be
good news indeed for patients with severe sepsis and
septic shock.
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